EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway

October 19, 2026 updated by: Rhythm Pharmaceuticals, Inc.

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Trial: Multiple Independent Sub-studies of Setmelanotide in Patients With POMC/PCSK1, LEPR, NCOA1(SRC1), or SH2B1 Gene Variants in the Melanocortin-4 Receptor Pathway

The protocol describes a randomized, double-blind, placebo-controlled trial with independent sub-studies of setmelanotide in participants with obesity and at least one of the specific gene variants in the Melanocortin-4 Receptor pathway:

  • Pro-opiomelanocortin (POMC) or proprotein convertase subtilisin/kexin type 1 (PCSK1; Sub-study 035a)
  • Leptin receptor (LEPR; Sub-study 035b)
  • Nuclear receptor coactivator 1 (NCOA1; steroid receptor coactivator 1 [SCR1]; Sub-study 035c)
  • Steroid receptor coactivator-1 homology 2 B adapter protein 1 (SH2B1; Sub-study 035d)

The objectives and endpoints are identical for these sub-studies.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Actual)

296

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

    • Alberta
      • Edmonton, Alberta, Canada, T6G 2E1
        • University of Alberta - Alberta Diabetes Institute (ADI)
    • Ontario
      • Toronto, Ontario, Canada, M5G 1X8
        • The Hospital for Sick Children
      • Lyon, France, 69677
        • GH Est Hopital Femme Mere Enfant
      • Paris, France, 75651
        • Hu Pitie Salpetriere Aphp
      • Paris, France, 75771
        • Hopital Armand Trousseau
      • Pessac, France, 33604
        • Centre Hospitalier Universitaire (CHU) de Bordeaux
      • Saint-Denis, France, 97400
        • Hôpital Félix Guyon Bellepierre
      • Toulouse, France
        • CHU de Toulouse Hopital des Enfants
      • Berlin, Germany, 10117
        • Charite - Universitatsmedizin Berlin
      • Frankfurt, Germany, 60596
        • Endokrinologikum Frankfurt
      • Leipzig, Germany, 04103
        • Universitaetsklinikum Leipzig
      • Ulm, Germany, 89075
        • Universitaetsklinikum Ulm
      • Rio, Greece, 26504
        • University of Patras School of Medicine
      • Petah Tikva, Israel, 49372
        • Hasharon Hospital
      • Ramat Gan, Israel, 52621
        • Chaim Sheba MC, Safra Children's Hospital
      • Rotterdam, Netherlands, 3015 GD
        • Erasmus Medisch Centrum
      • San Juan, Puerto Rico, 00925-253
        • University of Puerto Rico
      • San Juan, Puerto Rico, 00927
        • Puerto Rico Consortium for Clinical Investigation, Inc.
      • Barcelona, Spain, 08950
        • Hospital Sant Joan de Deu, Barcelona
      • Cadiz, Spain
        • Puerta del Mar University Hospital
      • Madrid, Spain, 28040
        • Hospital Fundación Jimenez Díaz
      • Málaga, Spain, 29010
        • Hospital Universitario Virgen de la Victoria de Málaga
      • Valencia, Spain, 46014
        • Hospital General de Valencia
      • Bristol, United Kingdom, BS2 8AE
        • Bristol Royal Hospital for Children
      • Cambridge, United Kingdom, CB2 0QQ
        • University of Cambridge
      • Liverpool, United Kingdom, L9 7AL
        • Aintree University Hospital
      • London, United Kingdom, W2 1NY
        • Imperial College Healthcare Trust
      • London, United Kingdom, NW1 2PG
        • London Medical - The London Diabetes Centre
      • London, United Kingdom, WC1E6JF
        • University College London Hospitals NHS Foundation Trust
      • Manchester, United Kingdom, M13 9WL
        • Manchester Children's Hospital
    • Arizona
      • Phoenix, Arizona, United States, 85016
        • Phoenix Children's Hospital
      • Scottsdale, Arizona, United States, 85258
        • HonorHealth Bariatric Center
    • California
      • Los Angeles, California, United States, 90027
        • Children's Hospital Los Angeles
    • Colorado
      • Aurora, Colorado, United States, 80045
        • Children's Hospital Colorado
    • Connecticut
      • New Haven, Connecticut, United States, 06519
        • Yale Center for Clinical Investigation
    • Florida
      • Altamonte Springs, Florida, United States, 32701
        • Advent Health
      • Gainesville, Florida, United States, 32610
        • University of Florida
    • Georgia
      • Suwanee, Georgia, United States, 30024
        • InQuest Medical Research
    • Massachusetts
      • Worcester, Massachusetts, United States, 01655
        • UMASS Memorial Medical Center
    • Michigan
      • Ann Arbor, Michigan, United States, 48105
        • University of Michigan
      • Dearborn, Michigan, United States, 48126-2619
        • Metro Detroit Endocrinology Center
    • Minnesota
      • Rochester, Minnesota, United States, 55902
        • Mayo Clinic
    • Mississippi
      • Madison, Mississippi, United States, 39110
        • Mississippi Center for Advanced Medicine
    • Missouri
      • Chesterfield, Missouri, United States, 63017
        • St. Luke's Hospital
      • Kansas City, Missouri, United States, 64108
        • Children's Mercy
      • St Louis, Missouri, United States, 63130
        • Washington University in St. Louis
    • New York
      • Buffalo, New York, United States, 14260
        • University of Buffalo
      • New York, New York, United States, 10032
        • Columbia University
      • New York, New York, United States, 10029
        • Mount Sinai Hospital
      • New York, New York, United States, 10029
        • Metropolitan Hospital Center
      • Staten Island, New York, United States, 10306
        • Ten's Medical Center - Pediatric Endocrinology Clinic
    • Ohio
      • Cincinnati, Ohio, United States, 45229
        • Cincinnati Children's Hospital Medical Center
      • Cleveland, Ohio, United States, 44195
        • Cleveland Clinic
    • Oregon
      • Portland, Oregon, United States, 97239
        • Oregon Health & Science University
    • Pennsylvania
      • Danville, Pennsylvania, United States, 17822
        • Geisinger Clinic
      • Philadelphia, Pennsylvania, United States, 19104
        • Children's Hospital of Philadelphia
      • Pittsburgh, Pennsylvania, United States, 15213
        • UPMC Montefiore
    • Tennessee
      • Nashville, Tennessee, United States, 37232
        • Vanderbilt University School of Medicine
    • Texas
      • Amarillo, Texas, United States, 79106
        • Texas Tech
      • Houston, Texas, United States, 77030
        • Texas Children's Hospital
      • Houston, Texas, United States, 77084
        • Biopharma Informatic
      • McAllen, Texas, United States, 78503
        • Rio Grande Valley Endocrine Center
      • Plano, Texas, United States, 75093
        • Endocrine Associates of Dallas and Plano
    • Washington
      • Tacoma, Washington, United States, 98405
        • MultiCare Health System Institute for Research and Innovation
    • West Virginia
      • Morgantown, West Virginia, United States, 26506
        • West Virginia University
    • Wisconsin
      • Marshfield, Wisconsin, United States, 54449
        • Marshfield Clinic Research Foundation, a Division of Marshfield Clinic, Inc

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

6 years to 65 years (Child, Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Description

Inclusion Criteria:

  • Participants must have a pre-identified:

    • Heterozygous genetic variant in the POMC gene or PCSK1 gene
    • Heterozygous genetic variant in the LEPR gene
    • Homozygous, heterozygous, or compound heterozygous variant in the NCOA1 (SRC1)
    • Homozygous, heterozygous, or compound heterozygous variant in SH2B1 gene, or chromosomal 16p11.2 deletion encompassing the SH2B1 gene
  • Between 6 and 65 years of age at the time of provision of informed consent/assent

  • Obesity, defined as body mass index (BMI) ≥30 kg/m^2 for participants ≥18 years of age or BMI ≥95th percentile for age and gender for participants 6 up to 17 years of age

  • Participant and/or parent or guardian is able to understand and comply with the requirements of the study and is able to understand and sign the written informed consent/assent

  • Participant and/or parent or guardian reports that participant experienced childhood obesity, defined as the participant and/or parent or guardian reporting that the participant had obesity or was significantly overweight during childhood

  • Agree to use a highly effective form of contraception throughout the study and for 90 days following the study

  • Reported history of lifestyle intervention of diet and exercise

  • Symptoms or behaviors of hyperphagia persistent during the participant's life, including manifestations in childhood, as determined by the Investigator at screening.

Key Exclusion Criteria:

  • Weight loss of 2% or greater in the previous 3 months
  • Bariatric surgery or procedure within the previous 6 months
  • Significant psychiatric disorder(s)
  • Suicidal ideation, attempt or behavior
  • Clinically significant pulmonary, cardiac, endocrine/metabolic, hepatic or oncologic disease
  • Glycated hemoglobin (HbA1C) >10% at Screening
  • History of significant liver disease or severe kidney disease
  • History or close family history (parents or siblings) of melanoma, or participant history of oculocutaneous albinism
  • Significant dermatologic findings relating to melanoma or pre-melanoma skin lesions (excluding non-invasive basal or squamous cell lesion)
  • Participation in any clinical study with an investigational drug/device within 3 months prior to the first day of dosing
  • Previously enrolled in a clinical study involving setmelanotide or any previous exposure to setmelanotide
  • Significant hypersensitivity to any excipient in the study drug
  • If female, pregnant or breastfeeding

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Triple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: POMC or PCSK1 variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Experimental: LEPR variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Experimental: NCOA1 (SRC1) variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

Experimental: SH2B1 variant

1:1 Randomization

Subcutaneous Injection

Subcutaneous Injection

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment Period: Percent Change From Baseline in Body Mass Index (BMI)
Time Frame: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kilograms (kg)/(height in meters [m])^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration. An analysis of covariance (ANCOVA) model was used to calculate the least-squares mean with randomization stratification factors and baseline value as a covariate.

Baseline, Week 52

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Treatment Period: Percentage of Participants Who Achieved at Least a 5% Reduction in Baseline BMI
Time Frame: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants Aged ≥18 Years): Percent Change From Baseline in Body Weight
Time Frame: Baseline, Week 52

Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration

Baseline, Week 52
Treatment Period (Participants Aged ≥12 Years): Percent Change From Baseline in Weekly Average Most Hunger Score
Time Frame: Baseline, Week 52

Participants ≥12 years of age who were able to validly and reliably self-report were administered "Hunger Questions for Participants ≥12 Years of Age©." The 'most hunger' item was designed to be evaluated separately and was averaged on a weekly basis. Participants were asked 'In the last 24 hours, how hungry did you feel when you were the most hungry?' and rated their hunger on an 11-point numeric rating scale ranging from 0 to 10 (0 = not hungry at all and 10 = hungriest possible). Data reported are for mean percent change from baseline in the weekly average daily most hunger score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Percentage of Participants Who Achieved at Least a 10% Reduction in Baseline BMI
Time Frame: Baseline, Week 52

BMI was calculated using participant's weight and height assessments as weight in kg/(height in m)^2. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI Z-score
Time Frame: Baseline, Week 52

BMI z-scores were calculated according to the Centers for Disease Control and Prevention (CDC) Growth Charts and according to participant's gender and age at screening. A Z-score of 0 is equal to the mean of a reference population (i.e., healthy, age and sex-matched individuals). A decrease in BMI Z-score (< 0) indicates a reduction in BMI from Baseline whereas an increase in BMI-Z score (> 0) indicated an increase in BMI from Baseline. Data reported are for mean percent change from baseline in BMI Z-score. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants <18 Years): Percent Change From Baseline in BMI 95th Percentile
Time Frame: Baseline, Week 52

The percentage change from baseline in BMI 95th percentile was calculated as ([BMI at Week 52 / BMI 95th percentile]) - [BMI at baseline / BMI 95th percentile])*100. BMI percentile scores are measures of relative weight adjusted for child age and gender. The percent of the BMI 95th percentile score expresses the participant's BMI as a percentage of the Centers for Disease Control (CDC) 95th percentile reference population. Data reported are for mean percent change from baseline in BMI 95th percentile. Baseline was defined as the most recent measurement prior to the first administration of study drug.

Baseline, Week 52
Treatment Period: Percent Change From Baseline in Waist Circumference
Time Frame: Baseline, Week 52

The waist circumference (in centimeters [cm]) was measured according to the National Heart, Lung, and Blood Institute (NHLBI) criteria. Data reported are for mean percent change from baseline in waist circumference. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Number of Participants With Treatment-emergent Adverse Events (TEAEs)
Time Frame: Baseline up to 60 weeks

TEAEs were defined as any untoward medical occurrence temporally associated with the use of study treatment, whether or not considered related to the study treatment that happened on or after the date of the first study treatment administration. A summary of all Serious Adverse Events and Other Adverse Events (nonserious) regardless of causality is located in the 'Reported Adverse Events' Section.

Baseline up to 60 weeks
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Physical Functioning Score on the Impact of Weight on Quality of Life (IWQOL)-Lite
Time Frame: Baseline, Week 52

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire. The physical function domain comprised 11 items which had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The score of each item was summed to calculate the raw score. The raw score range of the physical function domain was 11-55 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in physical functioning score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy
Time Frame: Baseline, Week 52

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire. The physical comfort domain comprised 6 items which used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw score. The raw score range of the physical function domain was 6-30 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Physical Comfort Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants ≥18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Lite
Time Frame: Baseline, Week 52

The IWQOL-Lite is a validated 31-item self-reported measure of obesity-specific quality of life questionnaire which comprised of 5 domains (physical function, self-esteem, sexual life, distress and work) and had 5 response items: Always True=5, Usually True=4, Sometimes True=3, Rarely True=2, Never True=1. The items were summed to calculate the raw total score. The raw total score range was 31-155 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Lite. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period (Participants 11 to <18 Years): Percent Change From Baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy
Time Frame: Baseline, Week 52

The IWQOL-Kids-Parent-Proxy is a psychometrically validated 27-item self-reported measure of obesity-specific quality of life questionnaire and comprised of 4 domains (physical comfort, body esteem, social life, family relations) and used a 5-point Likert scale: Always True=1, Usually True=2, Sometimes True=3, Rarely True=4, Never True=5. The items were summed to calculate the raw total score. The raw total score range was 27 to 135 and was transformed on a scale of 0 to 100, where 100 represented the best quality of life. The transformed score was calculated as (maximum score - raw score) / (maximum score - minimum score) *100. Data reported are for mean percent change from baseline in Impact on Quality of Life Total Score on the IWQOL-Kids-Parent-Proxy. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52
Treatment Period: Percent Change From Baseline in Body Weight in Setmelanotide Initial Responders Versus Placebo
Time Frame: Baseline, Week 52

Initial responders were defined as setmelanotide treated participants with ≥5% body weight loss (≥18 years of age) or a decrease in BMI by ≥3% (<18 years of age) at the time of consecutive 12 weeks with the increased 3.0 mg/day or with final increased dose level. Data reported are for mean percent change from baseline in body weight measured in kg. Baseline was defined as the last available measurement taken prior to the start of treatment administration.

Baseline, Week 52

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Investigators

  • Study Chair: David Meeker, MD, Rhythm Pharmaceuticals, Inc.

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

April 26, 2022

Primary Completion (Actual)

December 19, 2025

Study Completion (Actual)

June 30, 2026

Study Registration Dates

First Submitted

September 30, 2021

First Submitted That Met QC Criteria

October 13, 2021

First Posted (Actual)

October 26, 2021

Study Record Updates

Last Update Posted (Actual)

November 12, 2026

Last Update Submitted That Met QC Criteria

October 19, 2026

Last Verified

October 1, 2026

More Information

Terms related to this study

Other Study ID Numbers

  • RM-493-035

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

Yes

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.